【摘要】 目的探讨瑞替普酶用于急性心肌梗死溶栓治疗的有效性及安全性。方法将符合标准的患者93例,随机分为观察组(应用瑞替普酶)44例,对照组(应用尿激酶)49例。在常规治疗的基础上,分别给予静脉注射瑞替普酶和尿激酶,比较两组患者冠状动脉再通率以及出血发生率。结果观察组的血管再通率和出院时生存率都与对照组存在显著性差异(P<0.05)。观察组的出血发生率显著低于对照组(P<0.05)。结论瑞替普酶治疗AMI可以显著提高冠状动脉的再灌注率,安全方便,适用于基层临床应用。更多还原

【Abstract】 Objective To investigate the efficacy and safety of intravenous thrombo1ytic therapy by using Reteplase(r-PA)in acute myocardial infarction(AMI). Methods Ninety-three cases of AMI were randomized to observation group (44 cases receiving r-PA)and control group(49 cases). On the basis of routine treatment for both groups,r-PA was added to the observation group and urokinase was added to the control group. The recanalization rate and the bleeding rate were observed.Results The recanalization rate and the survival rate showed obvious differences between the observation group and the control group,and the bleeding rate of the observation group were significantly lower than that of the control group. Conclusion r-PA can significantly improve the coronary reperfusion rate in the treatment of AMI,safe and convenient and suitable for the primary clinical application.更多还原